How many drugs treat Gingivostomatitis?

Drug Landscape tracks 8 marketed treatments for Gingivostomatitis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/gingivostomatitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Gingivostomatitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Gingivostomatitis (disease) competitive landscape: 8 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

8 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Gingivostomatitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Minocycline Hydrochloride	MINOCYCLINE	Rempex	Tetracycline-class Drug		1971-01-01
Abelcet	AMPHOTERICIN B	Astellas Pharma	Lipid-based Polyene Antifungal [EPC]		1964-01-01
Demethylchlortetracycline	DEMECLOCYCLINE	Pfizer	Tetracycline-class Antimicrobial	Estrogen receptor beta	1960-01-01
Penicillin G Potassium In Plastic Container	Benzylpenicillin	Pfizer	Penicillin-class Antibacterial		1947-01-01
Meclan	MECLOCYCLINE	Johnson And Johnson	meclocycline
penicillin	penicillin	Karlstad University		Bacterial penicillin-binding protein, Beta-lactamase, Beta-lactamase TEM
Phenoxymethylpenicillin	Phenoxymethylpenicillin	Katarina Hedin		Bacterial penicillin-binding protein, Penicillin-binding protein 1A
Minocyclin	Minocyclin	University of Southern California		30S ribosomal protein S4, 30S ribosomal protein S9, Tetracycline resistance protein, class B

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 2 drugs in Gingivostomatitis
Astellas Pharma · 1 drug in Gingivostomatitis
Johnson And Johnson · 1 drug in Gingivostomatitis
Karlstad University · 1 drug in Gingivostomatitis
Katarina Hedin · 1 drug in Gingivostomatitis
Rempex · 1 drug in Gingivostomatitis
· 1 drug in Gingivostomatitis
University of Southern California · 1 drug in Gingivostomatitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Gingivostomatitis:

Cite this brief

Drug Landscape (2026). Gingivostomatitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/gingivostomatitis. Accessed 2026-06-10.

Gingivostomatitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing